Circulating tumor cells in solid tumor in metastatic and localized stages

Area of Science:

• Oncology
• Cellular Biology
• Diagnostic Medicine

Background:

• Circulating tumor cells (CTCs) are shed from primary tumors into the bloodstream.
• Their detection and quantification are vital for cancer diagnosis, staging, and monitoring treatment response.
• Epithelial tumors represent a significant proportion of cancer diagnoses.

Purpose of the Study:

• To investigate the presence and levels of CTCs in patients with breast, colorectal, and prostate cancer.
• To correlate CTC detection with disease stage (localized vs. metastatic).
• To evaluate the utility of CTCs as a biomarker in these epithelial tumor types.

Main Methods:

• A cohort of 438 breast, 195 colorectal, and 50 prostate cancer patients was studied.
• CTC quantification was performed using the CellSpotter Analyzer.
• Patient groups included both localized and metastatic disease stages.

Main Results:

• 31.5% of cancer patients exhibited >=2 CTCs/7.5 mL, compared to none in healthy volunteers (p<0.001).
• Metastatic disease showed a significantly higher prevalence of >=2 CTCs/7.5 mL (62.3%) versus localized disease (14.0%) (p<0.001).
• CTC presence correlated with tumor stage across all three cancer types, with no significant inter-tumor type differences in cell counts.

Conclusions:

• The presence of >2 CTCs/7.5 mL is common in metastatic cancers.
• Localized cancer patients with >2 CTCs/7.5 mL warrant further investigation for prognostic and predictive value.
• CTC detection serves as a valuable indicator of metastatic status in epithelial cancers.